Nuvation Bio Inc. Business Acquisition, Transaction Costs
Nuvation Bio Inc. (NUVB) had Business Acquisition, Transaction Costs of $3.21 million as of 2020-12-31, per its 10-K/A filed 2021-05-21.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Description
us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts · last filed 2021-05-21
- 2020-12-31: Business Acquisition, Transaction Costs $3.21M; Business Acquisition, Transaction Costs as first filed $3.39M.
- 2020-09-30: Business Acquisition, Transaction Costs $3.39M.
- 2020-06-30: Business Acquisition, Transaction Costs $3.39M.
| Period end | Business Acquisition, Transaction Costs | Business Acquisition, Transaction Costs as first filed |
|---|---|---|
| 2020-12-31 | $3.21M 10-K/A · filed 2021-05-21 | $3.39M 10-K · filed 2021-03-11 |
| 2020-09-30 | $3.39M 10-Q · filed 2020-11-16 | |
| 2020-06-30 | $3.39M 10-Q · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |